1. Home
  2. BLRX vs OPXS Comparison

BLRX vs OPXS Comparison

Compare BLRX & OPXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • OPXS
  • Stock Information
  • Founded
  • BLRX 2003
  • OPXS 1987
  • Country
  • BLRX Israel
  • OPXS United States
  • Employees
  • BLRX N/A
  • OPXS N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • OPXS Electronic Components
  • Sector
  • BLRX Health Care
  • OPXS Technology
  • Exchange
  • BLRX Nasdaq
  • OPXS Nasdaq
  • Market Cap
  • BLRX 54.1M
  • OPXS 54.2M
  • IPO Year
  • BLRX 2011
  • OPXS N/A
  • Fundamental
  • Price
  • BLRX $0.46
  • OPXS $8.31
  • Analyst Decision
  • BLRX Strong Buy
  • OPXS
  • Analyst Count
  • BLRX 2
  • OPXS 0
  • Target Price
  • BLRX $11.50
  • OPXS N/A
  • AVG Volume (30 Days)
  • BLRX 328.2K
  • OPXS 19.1K
  • Earning Date
  • BLRX 11-18-2024
  • OPXS 11-12-2024
  • Dividend Yield
  • BLRX N/A
  • OPXS N/A
  • EPS Growth
  • BLRX N/A
  • OPXS 132.50
  • EPS
  • BLRX N/A
  • OPXS 0.61
  • Revenue
  • BLRX $17,048,000.00
  • OPXS $32,628,999.00
  • Revenue This Year
  • BLRX N/A
  • OPXS N/A
  • Revenue Next Year
  • BLRX N/A
  • OPXS N/A
  • P/E Ratio
  • BLRX N/A
  • OPXS $13.85
  • Revenue Growth
  • BLRX N/A
  • OPXS 34.17
  • 52 Week Low
  • BLRX $0.43
  • OPXS $3.76
  • 52 Week High
  • BLRX $1.93
  • OPXS $8.99
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 31.02
  • OPXS 59.73
  • Support Level
  • BLRX $0.43
  • OPXS $8.15
  • Resistance Level
  • BLRX $0.56
  • OPXS $8.47
  • Average True Range (ATR)
  • BLRX 0.06
  • OPXS 0.27
  • MACD
  • BLRX -0.01
  • OPXS 0.07
  • Stochastic Oscillator
  • BLRX 12.71
  • OPXS 85.32

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About OPXS Optex Systems Holdings Inc.

Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, and light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Richardson and Applied Optics Center Dallas. It generates maximum revenue from the Applied Optics Center Dallas segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor and others.

Share on Social Networks: